Autolus Therapeutics Q1 Earnings Call Highlights
Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year revenue guidance for the cell therapy. Chief Executive Officer Dr. Christian Itin said the company h
MarketBeat ·